- call +1-201-465-4211
- email sales@mrinsights.biz
Gonorrhea is a sexually transmitted disease (STD) that affects both men and women. The infection affects the genitals, rectum, and the throat. The treatment landscape typically involves the use of antibiotics with dual therapy dominating the market compared with monotherapy. As the market has a deep penetration of generics, the growth rate is expected to be moderate during the forecast period. Additionally, the advent of new antibiotic-resistant strains will continue to hinder the growth prospects.
Scope of the Report:
This report studies the Gonorrhea Therapeutics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Gonorrhea Therapeutics market by product type and applications/end industries.
The latest trend gaining momentum in the market is Advent of vaccine for prevention of gonorrhea. Gonorrhea is a major public health concern globally. It is considerably affecting the reproductive health of people and increasing the spread of human immunodeficiency virus (HIV). The currently available treatment regimen is unsuccessful in controlling the spread of Neisseria gonorrhoeae due to the rapid emergence of the antibiotic-resistant strains of this bacterium. Therefore, the prevention of the disease seems to be a more appropriate approach for controlling the spread of Neisseria gonorrhoeae.
One of the major drivers for this market is Rising prevalence of disease. The rising prevalence of gonorrhea is a major health concern globally. The disease follows chlamydial infection as the second most common STD in the US. The rising prevalence rate of gonorrhea is due to several factors such as growing awareness, increased healthcare access, availability of diagnostic tests, resistance patterns, reporting practices, and the financial constraints that limit the abilities of public healthcare officials to check the disease pattern precisely.
The global Gonorrhea Therapeutics market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Gonorrhea Therapeutics.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Bharat Pharmaceuticals
GlaxoSmithKline
Merck
Pfizer
Alopexx Pharmaceuticals
AstraZeneca
Debiopharm Group
Melinta Therapeutics
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Monotherapy
Dual Therapy
Market Segment by Applications, can be divided into
Clinics
Hospitals
Others
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Gonorrhea Therapeutics Market Overview
1.1 Product Overview and Scope of Gonorrhea Therapeutics
1.2 Classification of Gonorrhea Therapeutics by Types
1.2.1 Global Gonorrhea Therapeutics Revenue Comparison by Types (2017-2023)
1.2.2 Global Gonorrhea Therapeutics Revenue Market Share by Types in 2017
1.2.3 Monotherapy
1.2.4 Dual Therapy
1.3 Global Gonorrhea Therapeutics Market by Application
1.3.1 Global Gonorrhea Therapeutics Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Clinics
1.3.3 Hospitals
1.3.4 Others
1.4 Global Gonorrhea Therapeutics Market by Regions
1.4.1 Global Gonorrhea Therapeutics Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Gonorrhea Therapeutics Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Gonorrhea Therapeutics Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Gonorrhea Therapeutics Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Gonorrhea Therapeutics Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Gonorrhea Therapeutics Status and Prospect (2013-2023)
1.5 Global Market Size of Gonorrhea Therapeutics (2013-2023)
2 Manufacturers Profiles
2.1 Bharat Pharmaceuticals
2.1.1 Business Overview
2.1.2 Gonorrhea Therapeutics Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Bharat Pharmaceuticals Gonorrhea Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.2 GlaxoSmithKline
2.2.1 Business Overview
2.2.2 Gonorrhea Therapeutics Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 GlaxoSmithKline Gonorrhea Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.3 Merck
2.3.1 Business Overview
2.3.2 Gonorrhea Therapeutics Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Merck Gonorrhea Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.4 Pfizer
2.4.1 Business Overview
2.4.2 Gonorrhea Therapeutics Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Pfizer Gonorrhea Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.5 Alopexx Pharmaceuticals
2.5.1 Business Overview
2.5.2 Gonorrhea Therapeutics Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Alopexx Pharmaceuticals Gonorrhea Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.6 AstraZeneca
2.6.1 Business Overview
2.6.2 Gonorrhea Therapeutics Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 AstraZeneca Gonorrhea Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.7 Debiopharm Group
2.7.1 Business Overview
2.7.2 Gonorrhea Therapeutics Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Debiopharm Group Gonorrhea Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.8 Melinta Therapeutics
2.8.1 Business Overview
2.8.2 Gonorrhea Therapeutics Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Melinta Therapeutics Gonorrhea Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
3 Global Gonorrhea Therapeutics Market Competition, by Players
3.1 Global Gonorrhea Therapeutics Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Gonorrhea Therapeutics Players Market Share
3.2.2 Top 10 Gonorrhea Therapeutics Players Market Share
3.3 Market Competition Trend
4 Global Gonorrhea Therapeutics Market Size by Regions
4.1 Global Gonorrhea Therapeutics Revenue and Market Share by Regions
4.2 North America Gonorrhea Therapeutics Revenue and Growth Rate (2013-2018)
4.3 Europe Gonorrhea Therapeutics Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Gonorrhea Therapeutics Revenue and Growth Rate (2013-2018)
4.5 South America Gonorrhea Therapeutics Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Gonorrhea Therapeutics Revenue and Growth Rate (2013-2018)
5 North America Gonorrhea Therapeutics Revenue by Countries
5.1 North America Gonorrhea Therapeutics Revenue by Countries (2013-2018)
5.2 USA Gonorrhea Therapeutics Revenue and Growth Rate (2013-2018)
5.3 Canada Gonorrhea Therapeutics Revenue and Growth Rate (2013-2018)
5.4 Mexico Gonorrhea Therapeutics Revenue and Growth Rate (2013-2018)
6 Europe Gonorrhea Therapeutics Revenue by Countries
6.1 Europe Gonorrhea Therapeutics Revenue by Countries (2013-2018)
6.2 Germany Gonorrhea Therapeutics Revenue and Growth Rate (2013-2018)
6.3 UK Gonorrhea Therapeutics Revenue and Growth Rate (2013-2018)
6.4 France Gonorrhea Therapeutics Revenue and Growth Rate (2013-2018)
6.5 Russia Gonorrhea Therapeutics Revenue and Growth Rate (2013-2018)
6.6 Italy Gonorrhea Therapeutics Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Gonorrhea Therapeutics Revenue by Countries
7.1 Asia-Pacific Gonorrhea Therapeutics Revenue by Countries (2013-2018)
7.2 China Gonorrhea Therapeutics Revenue and Growth Rate (2013-2018)
7.3 Japan Gonorrhea Therapeutics Revenue and Growth Rate (2013-2018)
7.4 Korea Gonorrhea Therapeutics Revenue and Growth Rate (2013-2018)
7.5 India Gonorrhea Therapeutics Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Gonorrhea Therapeutics Revenue and Growth Rate (2013-2018)
8 South America Gonorrhea Therapeutics Revenue by Countries
8.1 South America Gonorrhea Therapeutics Revenue by Countries (2013-2018)
8.2 Brazil Gonorrhea Therapeutics Revenue and Growth Rate (2013-2018)
8.3 Argentina Gonorrhea Therapeutics Revenue and Growth Rate (2013-2018)
8.4 Colombia Gonorrhea Therapeutics Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Gonorrhea Therapeutics by Countries
9.1 Middle East and Africa Gonorrhea Therapeutics Revenue by Countries (2013-2018)
9.2 Saudi Arabia Gonorrhea Therapeutics Revenue and Growth Rate (2013-2018)
9.3 UAE Gonorrhea Therapeutics Revenue and Growth Rate (2013-2018)
9.4 Egypt Gonorrhea Therapeutics Revenue and Growth Rate (2013-2018)
9.5 Nigeria Gonorrhea Therapeutics Revenue and Growth Rate (2013-2018)
9.6 South Africa Gonorrhea Therapeutics Revenue and Growth Rate (2013-2018)
10 Global Gonorrhea Therapeutics Market Segment by Type
10.1 Global Gonorrhea Therapeutics Revenue and Market Share by Type (2013-2018)
10.2 Global Gonorrhea Therapeutics Market Forecast by Type (2018-2023)
10.3 Monotherapy Revenue Growth Rate (2013-2023)
10.4 Dual Therapy Revenue Growth Rate (2013-2023)
11 Global Gonorrhea Therapeutics Market Segment by Application
11.1 Global Gonorrhea Therapeutics Revenue Market Share by Application (2013-2018)
11.2 Gonorrhea Therapeutics Market Forecast by Application (2018-2023)
11.3 Clinics Revenue Growth (2013-2018)
11.4 Hospitals Revenue Growth (2013-2018)
11.5 Others Revenue Growth (2013-2018)
12 Global Gonorrhea Therapeutics Market Size Forecast (2018-2023)
12.1 Global Gonorrhea Therapeutics Market Size Forecast (2018-2023)
12.2 Global Gonorrhea Therapeutics Market Forecast by Regions (2018-2023)
12.3 North America Gonorrhea Therapeutics Revenue Market Forecast (2018-2023)
12.4 Europe Gonorrhea Therapeutics Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Gonorrhea Therapeutics Revenue Market Forecast (2018-2023)
12.6 South America Gonorrhea Therapeutics Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Gonorrhea Therapeutics Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Gonorrhea Therapeutics Picture
Table Product Specifications of Gonorrhea Therapeutics
Table Global Gonorrhea Therapeutics and Revenue (Million USD) Market Split by P
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
